Share Price and Basic Stock Data
Last Updated: January 29, 2026, 11:36 am
| PEG Ratio | 1.03 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ambar Protein Industries Ltd operates within the Edible Oils & Solvent Extraction industry, focusing on the production and distribution of food-grade oils. As of the latest reporting period, the company’s stock price stood at ₹190, with a market capitalization of ₹109 Cr. Over the past few years, Ambar has shown a consistent increase in revenue, recording sales of ₹345 Cr for FY 2023, which rose to ₹421 Cr for FY 2025, reflecting a robust growth trajectory. Quarterly sales figures have varied, with a notable drop to ₹68.61 Cr in September 2023, before rebounding to ₹85.72 Cr in December 2023. This fluctuation in sales is indicative of seasonal demand variations typical in the edible oils sector, which can be heavily influenced by factors such as agricultural yields and consumer trends. Overall, the trailing twelve months (TTM) revenue reached ₹469 Cr, signifying a strong operational performance despite short-term volatility in quarterly sales.
Profitability and Efficiency Metrics
Ambar Protein Industries has demonstrated commendable profitability metrics, with a reported net profit of ₹8 Cr and a return on equity (ROE) of 32.3%, which is significantly higher than the industry average. The operating profit margin (OPM) stood at 2.25%, reflecting operational efficiency in a highly competitive market. However, the OPM has shown variability, peaking at 4.76% in September 2024 before declining to 2.25% in September 2025. The interest coverage ratio (ICR) is robust at 7.32x, suggesting that the company comfortably meets its interest obligations, which is crucial given its borrowings of ₹23 Cr. Additionally, the company’s cash conversion cycle (CCC) of 34 days indicates effective management of working capital, enabling quicker turnover of inventory and receivables. These metrics collectively underscore Ambar’s strong financial health and operational efficacy, positioning it favorably among its peers in the sector.
Balance Sheet Strength and Financial Ratios
Ambar’s balance sheet reflects a solid financial foundation, with total assets reported at ₹71 Cr and total liabilities at ₹70 Cr, indicating a manageable debt level. The reserves have steadily increased from ₹19 Cr in March 2024 to ₹32 Cr in September 2025, showcasing the company’s ability to retain earnings for growth and stability. The debt-to-equity ratio stood at 0.74, which is relatively low compared to industry standards, indicating prudent financial management. Furthermore, the current ratio of 1.45 suggests that Ambar has sufficient liquidity to cover its short-term obligations. The price-to-book value (P/BV) ratio of 3.36x reflects market confidence in the company’s growth potential, though it is slightly elevated compared to typical sector ranges. The return on capital employed (ROCE) at 27.5% is impressive, indicating efficient use of capital in generating profits, which enhances investor confidence in the company’s long-term strategies.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ambar Protein Industries indicates a strong promoter presence, with promoters holding 71.48% of the company, reflecting significant insider confidence. The public shareholding stands at 28.51%, with a total of 3,177 shareholders as of September 2025, indicating a broad base of retail investors. The steady increase in promoter shareholding from 70.35% in December 2022 to the current level suggests a commitment to the company’s growth trajectory. However, the absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) may raise concerns regarding institutional backing. The consistent public shareholding ratio, along with the increasing number of shareholders, reflects growing investor interest in the company. This robust shareholding structure can potentially stabilize the stock price and mitigate volatility, enhancing overall market confidence.
Outlook, Risks, and Final Insight
The outlook for Ambar Protein Industries appears promising, driven by its strong revenue growth and profitability metrics. However, the company faces several risks, including fluctuations in raw material prices, which can significantly impact margins and profitability. Additionally, the volatility in quarterly sales, as evidenced by the drop in September 2023, poses a risk to consistent revenue generation. The lack of institutional investor participation may also limit stock liquidity and increase volatility. Despite these challenges, the company’s strong fundamentals, including a robust ROE and manageable debt levels, suggest that it is well-positioned to navigate potential headwinds. Looking ahead, Ambar’s ability to maintain its growth trajectory while managing risks effectively will be crucial for sustaining investor confidence and achieving long-term success in the competitive edible oils market.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modi Naturals Ltd | 457 Cr. | 343 | 610/308 | 12.5 | 107 | 0.00 % | 18.7 % | 29.2 % | 10.0 |
| IEL Ltd | 89.6 Cr. | 6.87 | 10.3/4.00 | 3.37 | 0.00 % | 2.51 % | 1.91 % | 1.00 | |
| Evexia Lifecare Ltd | 312 Cr. | 1.66 | 3.30/1.52 | 218 | 3.02 | 0.00 % | 0.30 % | 0.32 % | 1.00 |
| Diligent Industries Ltd | 54.4 Cr. | 2.28 | 3.95/1.45 | 21.2 | 2.79 | 0.00 % | 7.06 % | 6.09 % | 1.00 |
| CIAN Agro Industries & Infrastructure Ltd | 3,220 Cr. | 1,150 | 3,633/321 | 1,586 | 33.0 | 0.00 % | 8.54 % | 1.06 % | 10.0 |
| Industry Average | 9,960.36 Cr | 155.82 | 128.37 | 37.26 | 0.19% | 14.31% | 12.90% | 4.29 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 75.77 | 94.92 | 90.00 | 93.22 | 68.61 | 85.72 | 89.51 | 93.04 | 88.95 | 111.82 | 127.81 | 117.27 | 111.66 |
| Expenses | 74.30 | 92.42 | 89.17 | 90.62 | 67.04 | 81.90 | 90.26 | 90.10 | 84.72 | 107.00 | 124.02 | 115.13 | 109.15 |
| Operating Profit | 1.47 | 2.50 | 0.83 | 2.60 | 1.57 | 3.82 | -0.75 | 2.94 | 4.23 | 4.82 | 3.79 | 2.14 | 2.51 |
| OPM % | 1.94% | 2.63% | 0.92% | 2.79% | 2.29% | 4.46% | -0.84% | 3.16% | 4.76% | 4.31% | 2.97% | 1.82% | 2.25% |
| Other Income | 0.13 | 0.12 | 0.14 | 0.12 | 0.12 | 0.12 | 0.31 | 0.22 | 0.22 | 0.19 | 0.20 | 0.19 | 0.18 |
| Interest | 0.66 | 0.65 | 0.60 | 0.64 | 0.63 | 0.69 | 0.50 | 0.56 | 0.56 | 0.57 | 0.58 | 0.53 | 0.45 |
| Depreciation | 0.32 | 0.32 | 0.31 | 0.33 | 0.26 | 0.39 | 0.34 | 0.32 | 0.32 | 0.46 | 0.21 | 0.33 | 0.34 |
| Profit before tax | 0.62 | 1.65 | 0.06 | 1.75 | 0.80 | 2.86 | -1.28 | 2.28 | 3.57 | 3.98 | 3.20 | 1.47 | 1.90 |
| Tax % | 27.42% | 37.58% | 116.67% | 27.43% | 2.50% | 45.10% | -64.84% | 24.56% | 24.65% | 29.15% | 22.19% | 48.98% | -5.26% |
| Net Profit | 0.46 | 1.03 | -0.02 | 1.26 | 0.78 | 1.56 | -0.45 | 1.72 | 2.69 | 2.82 | 2.48 | 0.75 | 2.00 |
| EPS in Rs | 0.80 | 1.79 | -0.03 | 2.19 | 1.36 | 2.71 | -0.78 | 2.99 | 4.68 | 4.90 | 4.31 | 1.30 | 3.48 |
Last Updated: December 28, 2025, 5:29 am
Below is a detailed analysis of the quarterly data for Ambar Protein Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 111.66 Cr.. The value appears to be declining and may need further review. It has decreased from 117.27 Cr. (Jun 2025) to 111.66 Cr., marking a decrease of 5.61 Cr..
- For Expenses, as of Sep 2025, the value is 109.15 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 115.13 Cr. (Jun 2025) to 109.15 Cr., marking a decrease of 5.98 Cr..
- For Operating Profit, as of Sep 2025, the value is 2.51 Cr.. The value appears strong and on an upward trend. It has increased from 2.14 Cr. (Jun 2025) to 2.51 Cr., marking an increase of 0.37 Cr..
- For OPM %, as of Sep 2025, the value is 2.25%. The value appears strong and on an upward trend. It has increased from 1.82% (Jun 2025) to 2.25%, marking an increase of 0.43%.
- For Other Income, as of Sep 2025, the value is 0.18 Cr.. The value appears to be declining and may need further review. It has decreased from 0.19 Cr. (Jun 2025) to 0.18 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Sep 2025, the value is 0.45 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.53 Cr. (Jun 2025) to 0.45 Cr., marking a decrease of 0.08 Cr..
- For Depreciation, as of Sep 2025, the value is 0.34 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.33 Cr. (Jun 2025) to 0.34 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.90 Cr.. The value appears strong and on an upward trend. It has increased from 1.47 Cr. (Jun 2025) to 1.90 Cr., marking an increase of 0.43 Cr..
- For Tax %, as of Sep 2025, the value is -5.26%. The value appears to be improving (decreasing) as expected. It has decreased from 48.98% (Jun 2025) to -5.26%, marking a decrease of 54.24%.
- For Net Profit, as of Sep 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.75 Cr. (Jun 2025) to 2.00 Cr., marking an increase of 1.25 Cr..
- For EPS in Rs, as of Sep 2025, the value is 3.48. The value appears strong and on an upward trend. It has increased from 1.30 (Jun 2025) to 3.48, marking an increase of 2.18.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:15 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 160 | 157 | 168 | 195 | 206 | 231 | 284 | 313 | 340 | 345 | 336 | 421 | 469 |
| Expenses | 159 | 155 | 167 | 193 | 203 | 227 | 278 | 305 | 330 | 338 | 328 | 406 | 455 |
| Operating Profit | 1 | 2 | 2 | 3 | 3 | 4 | 6 | 8 | 9 | 7 | 7 | 16 | 13 |
| OPM % | 1% | 1% | 1% | 1% | 1% | 2% | 2% | 2% | 3% | 2% | 2% | 4% | 3% |
| Other Income | 0 | 1 | 0 | 1 | 1 | 0 | 0 | -0 | 1 | 0 | 0 | 1 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
| Depreciation | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 2 | 1 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 13 | 11 |
| Tax % | 0% | 0% | 36% | 2% | 27% | 28% | 55% | 13% | 25% | 29% | 24% | 26% | |
| Net Profit | 0 | 2 | 1 | 2 | 2 | 2 | 1 | 3 | 4 | 3 | 3 | 10 | 8 |
| EPS in Rs | 0.14 | 2.70 | 1.51 | 4.19 | 3.74 | 3.53 | 2.17 | 6.00 | 7.74 | 4.89 | 5.48 | 16.78 | 13.99 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 100.00% | 0.00% | 0.00% | -50.00% | 200.00% | 33.33% | -25.00% | 0.00% | 233.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 150.00% | -100.00% | 0.00% | -50.00% | 250.00% | -166.67% | -58.33% | 25.00% | 233.33% |
Ambar Protein Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| TTM: | 32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 50% |
| 3 Years: | 29% |
| TTM: | 142% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| 1 Year: | 127% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 23% |
| 3 Years: | 21% |
| Last Year: | 32% |
Last Updated: September 5, 2025, 2:16 pm
Balance Sheet
Last Updated: December 4, 2025, 2:21 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | -4 | -3 | -1 | 0 | 2 | 4 | 5 | 9 | 13 | 16 | 19 | 29 | 32 |
| Borrowings | 6 | 6 | 8 | 10 | 18 | 24 | 27 | 27 | 33 | 29 | 26 | 26 | 23 |
| Other Liabilities | 5 | 4 | 5 | 7 | 5 | 19 | 11 | 8 | 12 | 11 | 11 | 10 | 10 |
| Total Liabilities | 12 | 13 | 17 | 23 | 31 | 53 | 49 | 50 | 64 | 62 | 61 | 71 | 70 |
| Fixed Assets | 4 | 4 | 6 | 6 | 6 | 7 | 22 | 21 | 21 | 20 | 19 | 18 | 18 |
| CWIP | 0 | 0 | 0 | 0 | 6 | 16 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 8 | 9 | 12 | 17 | 19 | 31 | 27 | 29 | 44 | 42 | 42 | 51 | 52 |
| Total Assets | 12 | 13 | 17 | 23 | 31 | 53 | 49 | 50 | 64 | 62 | 61 | 71 | 70 |
Below is a detailed analysis of the balance sheet data for Ambar Protein Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Reserves, as of Sep 2025, the value is 32.00 Cr.. The value appears strong and on an upward trend. It has increased from 29.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 3.00 Cr..
- For Borrowings, as of Sep 2025, the value is 23.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 26.00 Cr. (Mar 2025) to 23.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 70.00 Cr.. The value appears to be improving (decreasing). It has decreased from 71.00 Cr. (Mar 2025) to 70.00 Cr., marking a decrease of 1.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 18.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 52.00 Cr.. The value appears strong and on an upward trend. It has increased from 51.00 Cr. (Mar 2025) to 52.00 Cr., marking an increase of 1.00 Cr..
- For Total Assets, as of Sep 2025, the value is 70.00 Cr.. The value appears to be declining and may need further review. It has decreased from 71.00 Cr. (Mar 2025) to 70.00 Cr., marking a decrease of 1.00 Cr..
Notably, the Reserves (32.00 Cr.) exceed the Borrowings (23.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -4.00 | -6.00 | -7.00 | -15.00 | -20.00 | -21.00 | -19.00 | -24.00 | -22.00 | -19.00 | -10.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 3 | 2 | 3 | 8 | 3 | 2 | 3 | 4 | 10 | 15 | 15 | 18 |
| Inventory Days | 11 | 12 | 18 | 19 | 16 | 37 | 20 | 22 | 32 | 23 | 24 | 20 |
| Days Payable | 13 | 10 | 11 | 9 | 6 | 10 | 3 | 5 | 9 | 7 | 8 | 3 |
| Cash Conversion Cycle | 1 | 4 | 10 | 18 | 13 | 29 | 19 | 21 | 33 | 30 | 31 | 34 |
| Working Capital Days | -8 | -8 | -4 | -1 | -4 | -9 | -8 | -2 | 3 | 4 | 6 | 12 |
| ROCE % | 8% | 28% | 18% | 22% | 17% | 13% | 15% | 18% | 18% | 13% | 13% | 28% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 16.78 | 5.47 | 4.92 | 7.74 | 6.00 |
| Diluted EPS (Rs.) | 16.78 | 5.47 | 4.92 | 7.74 | 6.00 |
| Cash EPS (Rs.) | 19.06 | 7.75 | 7.11 | 9.97 | 8.09 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 60.39 | 43.60 | 38.13 | 33.21 | 25.48 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 60.39 | 43.60 | 38.13 | 33.21 | 25.48 |
| Revenue From Operations / Share (Rs.) | 733.26 | 586.19 | 600.13 | 590.87 | 544.87 |
| PBDIT / Share (Rs.) | 28.89 | 13.72 | 13.50 | 17.18 | 13.61 |
| PBIT / Share (Rs.) | 26.61 | 11.43 | 11.29 | 14.95 | 11.52 |
| PBT / Share (Rs.) | 22.66 | 7.16 | 6.88 | 10.27 | 6.92 |
| Net Profit / Share (Rs.) | 16.78 | 5.47 | 4.89 | 7.74 | 6.00 |
| PBDIT Margin (%) | 3.93 | 2.34 | 2.25 | 2.90 | 2.49 |
| PBIT Margin (%) | 3.62 | 1.95 | 1.88 | 2.53 | 2.11 |
| PBT Margin (%) | 3.09 | 1.22 | 1.14 | 1.73 | 1.27 |
| Net Profit Margin (%) | 2.28 | 0.93 | 0.81 | 1.30 | 1.10 |
| Return on Networth / Equity (%) | 27.79 | 12.54 | 12.83 | 23.30 | 23.54 |
| Return on Capital Employeed (%) | 41.06 | 23.61 | 24.19 | 34.46 | 30.62 |
| Return On Assets (%) | 13.68 | 5.12 | 4.51 | 6.93 | 6.86 |
| Long Term Debt / Equity (X) | 0.00 | 0.01 | 0.07 | 0.14 | 0.24 |
| Total Debt / Equity (X) | 0.74 | 1.02 | 1.34 | 1.72 | 1.86 |
| Asset Turnover Ratio (%) | 6.39 | 5.45 | 5.46 | 5.94 | 6.29 |
| Current Ratio (X) | 1.45 | 1.21 | 1.19 | 1.11 | 1.00 |
| Quick Ratio (X) | 0.83 | 0.61 | 0.63 | 0.42 | 0.39 |
| Inventory Turnover Ratio (X) | 20.84 | 16.08 | 13.93 | 14.65 | 18.92 |
| Interest Coverage Ratio (X) | 7.32 | 3.21 | 3.07 | 3.67 | 2.96 |
| Interest Coverage Ratio (Post Tax) (X) | 5.26 | 2.28 | 2.11 | 2.65 | 2.30 |
| Enterprise Value (Cr.) | 141.53 | 108.01 | 151.38 | 48.68 | 29.74 |
| EV / Net Operating Revenue (X) | 0.33 | 0.32 | 0.43 | 0.14 | 0.09 |
| EV / EBITDA (X) | 8.52 | 13.69 | 19.50 | 4.93 | 3.80 |
| MarketCap / Net Operating Revenue (X) | 0.27 | 0.24 | 0.35 | 0.05 | 0.01 |
| Price / BV (X) | 3.36 | 3.34 | 5.62 | 0.89 | 0.27 |
| Price / Net Operating Revenue (X) | 0.27 | 0.24 | 0.35 | 0.05 | 0.01 |
| EarningsYield | 0.08 | 0.03 | 0.02 | 0.26 | 0.85 |
After reviewing the key financial ratios for Ambar Protein Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For Diluted EPS (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For Cash EPS (Rs.), as of Mar 25, the value is 19.06. This value is within the healthy range. It has increased from 7.75 (Mar 24) to 19.06, marking an increase of 11.31.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.39. It has increased from 43.60 (Mar 24) to 60.39, marking an increase of 16.79.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.39. It has increased from 43.60 (Mar 24) to 60.39, marking an increase of 16.79.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 733.26. It has increased from 586.19 (Mar 24) to 733.26, marking an increase of 147.07.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.89. This value is within the healthy range. It has increased from 13.72 (Mar 24) to 28.89, marking an increase of 15.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is 26.61. This value is within the healthy range. It has increased from 11.43 (Mar 24) to 26.61, marking an increase of 15.18.
- For PBT / Share (Rs.), as of Mar 25, the value is 22.66. This value is within the healthy range. It has increased from 7.16 (Mar 24) to 22.66, marking an increase of 15.50.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For PBDIT Margin (%), as of Mar 25, the value is 3.93. This value is below the healthy minimum of 10. It has increased from 2.34 (Mar 24) to 3.93, marking an increase of 1.59.
- For PBIT Margin (%), as of Mar 25, the value is 3.62. This value is below the healthy minimum of 10. It has increased from 1.95 (Mar 24) to 3.62, marking an increase of 1.67.
- For PBT Margin (%), as of Mar 25, the value is 3.09. This value is below the healthy minimum of 10. It has increased from 1.22 (Mar 24) to 3.09, marking an increase of 1.87.
- For Net Profit Margin (%), as of Mar 25, the value is 2.28. This value is below the healthy minimum of 5. It has increased from 0.93 (Mar 24) to 2.28, marking an increase of 1.35.
- For Return on Networth / Equity (%), as of Mar 25, the value is 27.79. This value is within the healthy range. It has increased from 12.54 (Mar 24) to 27.79, marking an increase of 15.25.
- For Return on Capital Employeed (%), as of Mar 25, the value is 41.06. This value is within the healthy range. It has increased from 23.61 (Mar 24) to 41.06, marking an increase of 17.45.
- For Return On Assets (%), as of Mar 25, the value is 13.68. This value is within the healthy range. It has increased from 5.12 (Mar 24) to 13.68, marking an increase of 8.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.74. This value is within the healthy range. It has decreased from 1.02 (Mar 24) to 0.74, marking a decrease of 0.28.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 6.39. It has increased from 5.45 (Mar 24) to 6.39, marking an increase of 0.94.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. It has increased from 1.21 (Mar 24) to 1.45, marking an increase of 0.24.
- For Quick Ratio (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has increased from 0.61 (Mar 24) to 0.83, marking an increase of 0.22.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 20.84. This value exceeds the healthy maximum of 8. It has increased from 16.08 (Mar 24) to 20.84, marking an increase of 4.76.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.32. This value is within the healthy range. It has increased from 3.21 (Mar 24) to 7.32, marking an increase of 4.11.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.26. This value is within the healthy range. It has increased from 2.28 (Mar 24) to 5.26, marking an increase of 2.98.
- For Enterprise Value (Cr.), as of Mar 25, the value is 141.53. It has increased from 108.01 (Mar 24) to 141.53, marking an increase of 33.52.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.33, marking an increase of 0.01.
- For EV / EBITDA (X), as of Mar 25, the value is 8.52. This value is within the healthy range. It has decreased from 13.69 (Mar 24) to 8.52, marking a decrease of 5.17.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.24 (Mar 24) to 0.27, marking an increase of 0.03.
- For Price / BV (X), as of Mar 25, the value is 3.36. This value exceeds the healthy maximum of 3. It has increased from 3.34 (Mar 24) to 3.36, marking an increase of 0.02.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.24 (Mar 24) to 0.27, marking an increase of 0.03.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.08, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ambar Protein Industries Ltd:
- Net Profit Margin: 2.28%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 41.06% (Industry Average ROCE: 14.31%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 27.79% (Industry Average ROE: 12.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.26
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.83
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 13 (Industry average Stock P/E: 128.37)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.74
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.28%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Edible Oils & Solvent Extraction | Block No. 351p2, 353p2 and 358, Panchratna Estate, Ahmedabad District Gujarat 382213 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pradeep C Khetani | Managing Director |
| Mr. Jayprakash J Vachhani | Whole Time Director |
| Mr. Shirishkumar D Patel | Director |
| Mr. Bharatbhai D Patel | Director |
| Mr. Dashrathbhai A Patel | Director |
| Mrs. Shobhanaben J Vachhani | Director |
| Mr. Gangaram Bhanjibhai Patel | Independent Director |
| Mr. Yogen Pranjivandas Patel | Independent Director |
| Mr. Narottam Chaturdas Tanna | Independent Director |
FAQ
What is the intrinsic value of Ambar Protein Industries Ltd?
Ambar Protein Industries Ltd's intrinsic value (as of 29 January 2026) is ₹251.48 which is 38.18% higher the current market price of ₹182.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹105 Cr. market cap, FY2025-2026 high/low of ₹433/170, reserves of ₹32 Cr, and liabilities of ₹70 Cr.
What is the Market Cap of Ambar Protein Industries Ltd?
The Market Cap of Ambar Protein Industries Ltd is 105 Cr..
What is the current Stock Price of Ambar Protein Industries Ltd as on 29 January 2026?
The current stock price of Ambar Protein Industries Ltd as on 29 January 2026 is ₹182.
What is the High / Low of Ambar Protein Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ambar Protein Industries Ltd stocks is ₹433/170.
What is the Stock P/E of Ambar Protein Industries Ltd?
The Stock P/E of Ambar Protein Industries Ltd is 13.0.
What is the Book Value of Ambar Protein Industries Ltd?
The Book Value of Ambar Protein Industries Ltd is 65.2.
What is the Dividend Yield of Ambar Protein Industries Ltd?
The Dividend Yield of Ambar Protein Industries Ltd is 0.00 %.
What is the ROCE of Ambar Protein Industries Ltd?
The ROCE of Ambar Protein Industries Ltd is 27.5 %.
What is the ROE of Ambar Protein Industries Ltd?
The ROE of Ambar Protein Industries Ltd is 32.3 %.
What is the Face Value of Ambar Protein Industries Ltd?
The Face Value of Ambar Protein Industries Ltd is 10.0.